Abstract
The aim of the work was to establish the spectrum of biological activity of new derivatives of 9-bromo-1,2,3,4-tetrahydroacridine due to the limited amount of literature data. In silico prediction of selected bromo-derivatives of hydrogenated acridines was performed using the SuperPred 3.0 web resource. The obtained results were compared with the results of prediction of active drugs that contain the acridine cycle in their structure - Tacrine, Amiridine and Amsacrine. Results ≤80% were taken into account. The most promising compound was 9-bromo-1,2,3,4-tetrahydroacridine. A common predicted target for bromide-hydrogenated acridines and all three drugs is DNA-(apurine or apyrimidine site) lyase with binding probabilities ranging from 82-97.5%. Common predicted targets for 9-bromo-1,2,3,4-tetrahydroacridine derivatives, Tacrine and Amsacrine are butyrylcholinesterase (90.4-98.2%) and transcription factor 1-α (92.02-98.01 %). Cathepsin D, toll-like receptor 8 and glucose transporter are promising common targets for further research, but it should be noted that the probability of binding in these drugs was below 80%. All selected compounds were tested for Lipinski's criteria. In addition, in silico prediction of the acute toxicity of bromo-derivatives of acridine was performed in rats with four types of administration. The safest compound according to the oral method of administration is the compound 9-bromo-2-tert-butyl-1,2,3,4-tetrahydroacridine (1570 mg/kg), while the compound 9-bromo-1,2 turned out to be more toxic than the others ,3,4-tetrahydroacridine (565.3 mg/kg). The estimated average lethal dose of Tacrine after a single oral dose to rats is 40 mg/kg. The prediction results confirmed the prospects of further research among the class of hydrogenated bromoderivatives of acridines.
References
Cem Yamali, Seyda Donmez. Recent developments in Tacrine-based as a therapeutic option for Alzheimer’s disease. Mini Rev Med Chem. 2023. 23 (7): 869–880.
2174/1389557523666221201145141
Mitra S., Muni M., Shawon N. J., Das R., Emran T. B., Sharma R. at all. Tacrine derivatives in neurological disorders: focus on molecular mechanism and neurotherapeutic potential. Oxid Med Cell Longev. 2022. 7252882.
https://doi.org/10.1155/2022/7252882
Qizilbash N., Whitehead A., Higgins J., Wilcock G., Scheider L., Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists’ Collaboration. JAMA. 1998. 280 (20): 1777–82. 10.1001/jama.280.20.1777
Hu S., Lin St. L., Schachner M. A fragment of cell adhesion molecules L1 reduces amyloid-β plaques in a mouse model of Alzheimer’s disease. Cell Death Diss 2022. 13 (1): 48.
1038/s41419-021-04348-6
Yang H., Jia H., Deng M., Zhang K., Liu Y., Cheng M., Xiao W., Design, synthesis and evaluation of OA-tacrine hybrids as chlolinesterase inhibitors with low neurotoxicity and hepatotoxicity against Alzheimer’s disease. J Enzyme Inhib Med Chem. 2023. 38 (1): 2192439. 10.1080/14756366.2023.2192439
Smetanin N.V., Varenichenko S.A., Zaliznaya E.V., Mazepa A.V., Farat O.K., Markov V.I. Functionalization of N-arylmaleimides by sp3 C–H bonds of hydroacridines (qinolines). Voprosy Khimii i Khimicheskoi Tekhnologii. 2020. 6: 165–170.
32434/0321-4095-2020-133-6-165-170
Smetanin N.V., Varenichenko S.A., Mazepa A.V., Farat O.K., Kharchenko A.V. Markov V.I. Atom-economic Michael reaction between hydroacridines and arylmaleimides without catalyst/additive. Voprosy Khimii i Khimicheskoi Tekhnologii. 2022. 5:102–109.
DOI: 10.32434/0321-4095-2022-144-5-102-109
Smetanin N.V., Tokarieva S.V., Varenichenko S.A., Farat O.K., Markov V.I. In silico prediction and molecular docking studies of biological activity of hydroacridine (quinoline) derivatives. Ukrainian Chemistry Journal. 2021. 5(87): 38–52.
doi: 10.33609/2708-129X.87.05.2021.38-52
Dunkel M., Günther S., Ahmed J., Wittig B., Preissner R. SuperPred: drug classification and target prediction Nucleic Acids Research. 2008. 1(36 Web Server issue):W55-9.
1093/nar/gkn307
Gallo K., Goede A., Preissner R., Gohlke B-O. SuperPred 3.0: drug classification and target prediction – a machine learning approach Nucleic Acids Research. 2022. 50(W1):W726–W731 https://doi.org/10.1093/nar/gkac297
Aihua Jiang, Hua Gao, Mark R Kelley, Xiaoxi Qiao. Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011. 51(1): 93–100
1016/j.visres.2010.10.008
Lilja A.M., Yu Luo, Qian-Sheng Yu, Röjdner J., Li Y., Marini A.M., Marutle A., Nordberg A., Greig N.H. Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. PLoS One. 2013. 8(1):e54887 10.1371/journal.pone.0054887
Noy-Porat T., Cohen O., Ehrlich S., Epstein E., Alcalay R., Ohad Mazor O. Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015. 19; 26(8): 1753–8
1021/acs.bioconjchem.5b00305
Mackman R.L., Mish M., Chin G., Perry J.K., Appleby T., Aktoudianakis V. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020. 24: 63(18):10188–10203.
1021/acs.jmedchem.0c00100
Wulff H., Christophersen P., Colussi P., Chandy K.G., Yarov-Yarovoy V. Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019. 18(5): 339–357
1038/s41573-019-0013-8
Kim J.J., Gharpure A., Teng J., Zhuang Y., Howard R.J., Zhu S., Noviello C.M., Walsh Jr R.M., Lindahl E., Hibbs R.E. Shared structural mechanisms of general anaesthetics and benzodiazepines. Nature. 2020. 585(7824): 303–308.
1038/s41586-020-2654-5
GUSAR-оnline [Електронний ресурс] – Режим доступу до ресурсу: http://www.waydrug.com/gusar/acutoxpredict.html.
Si-Yuan Pan, Yi Zhang, Bao-Feng Guo, Yi-Fan Han, Kam-Ming Ko. Tacrine and bis(7)-tacrine attenuate cycloheximide-induced amnesia in mice, with attention to acute toxicity. Basic Clin Pharmacol Toxicol. 2011 109(4): 261–5.
doi: 10.1111/j.1742-7843.2011.00715.x